ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 12

Examining Key Data from DAREON-8

, , ,

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
Now Viewing
EP. 12: Examining Key Data from DAREON-8
EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

  1. DAREON-8: Phase 1 Clinical Trial of Combination Therapy with BI 764532, a DLL3 Targeting T-Cell Engager
    1. Please share your opinions of the therapeutic potential of Bl 764532, an lgG-like T-cell engager, for its ability to induce selective T-cell mediated tumor cell lysis when added to SOC (carboplatin + etoposide + atezolizumab) for previously untreated patients with ES-SCLC:
    2. Is a commercial molecular assay currently available to identify the presence of the delta-like ligand 3 notch receptor in patients with SCLC?
    3. Are you encouraged by an overall response rate of 28% and a 54% disease control rate in the Phase I trial?
    4. For which line of therapy do you envision BI 764532, if approved?
    5. Based on the exclusion criteria for the dose escalation trial, are you concerned that this agent may be associated with cardiovascular, cerebrovascular, and/or immunosuppressive TRAEs?